Deal Watch: DelMar Takes On Unmet Need In Brain Cancer With Accurexa
Getting ready to take VAL-083 into Phase III in recurrent glioblastoma, DelMar also is partnering with Accurexa to develop an implantable wafer therapeutic combining the drug with other brain cancer chemotherapies. GW Pharmaceuticals sees a surge in its share price as speculation mounts about a possible takeout.
You may also be interested in...
GW Pharma High On Epilepsy Results, Plans 2017 NDA
The biotech announces another set of positive anti-seizure results for its marijuana-derived product.
PIPELINE WATCH - Four Launches, Two Approvals And Six Orphan Drug Designations
The table records clinical and regulatory developments using data from BioMedTracker. It lists all drugs for which an event was recorded from April 15 to April 21, 2016, divided by event type.
ICER’s Final NASH Report Urges Step Therapy, Specialist Prescribing, Equitable Access
When the first non-alcoholic steatohepatitis drugs reach market, the health cost watchdog says payers will be justified in setting step-therapy including weight-management efforts, while early prescribing should be by specialists.